147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN). - Burnett, A.; El Rassi, F.; Darbari, D.; Paulose, J.; Lainé, D.; Purkayastha, D.; Kato, G. (Journal of Sexual Medicine, 2020)